Switzerland
-
Polaroid Therapeutics joins Crohn’s & Colitis Foundation’s IBD Plexus to advance IBD research
Through its membership, PTx will gain access to longitudinal health data and biosamples from people living with IBD, with personal identifying information removed.
-
WHO issues first comprehensive clinical guidelines for flavovirus care amid ongoing Bundibugyo outbreak
The new framework sets out 16 evidence-based recommendations designed to strengthen patient care and improve survival rates during outbreaks.
-
Gavi mobilizes US$50M First Response Fund to fight Bundibugyo Ebola outbreak
The initiative will also involve coordination with World Health Organization, Africa Centres for Disease Control and Prevention, and UNICEF to ensure alignment with national outbreak response plans and immunization priorities.
-
Africa CDC signs landmark health sovereignty agreement with the Global Fund at WHA79
The partnership builds on Africa CDC’s recent efforts to accelerate the deployment of community health workers across the continent through collaborations with regional partners.
-
WHO renews five-year partnership with Gilead Sciences to eliminate deadly Kala-Azar disease
Since the partnership began, Gilead has supplied more than 1.1 million vials of AmBisome and contributed over US$18 million in funding.
-
SERB Pharmaceuticals acquires rights to Idefirix in US$133.6M deal with Hansa Biopharma
Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.
-
Roche signs landmark MPP agreement to increase Xofluza access in 129 countries
Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.
-
Big Catch-Up vaccination drive reaches 18M children, reversing pandemic immunity gaps
Programme implementation concluded on March 31, 2026, with the global initiative on track to exceed its target of reaching at least 21 million under-immunised children.
-
WHO adds long-acting injectables to opioid treatment options
Opioids bear responsibility for the largest portion of drug-related deaths globally, accounting for roughly 450,000 of the approximate 600,000 annual deaths linked to drug use.
-
Sandoz inks global deal for Samsung Bioepis’ Vedolizumab biosimilar
This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.